Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.35 |
| ▸ | HTR2B | P41595 | 8/20 | 0.35 |
| ▸ | HTR2A | P28223 | 7/20 | 0.35 |
| ▸ | AKT1 | P31749 | 3/20 | 0.32 |
| ▸ | RPS6KA1 | Q15418 | 3/20 | 0.32 |
| ▸ | PRKCA | P17252 | 1/20 | 0.32 |
| ▸ | GRK2 | P25098 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20207075 | 1.00 | HTR2C (0.35) | HTR2CHTR2BHTR2AAKT1RPS6KA1 | |
| SCHEMBL18374371 | 0.84 | SCN9A (0.42) | — | |
| Hydrochloric Acid SCHEMBL20191183 | 0.83 | SCN9A (0.41) | — | |
| Hydrochloric Acid SCHEMBL20191182 | 0.83 | SCN9A (0.41) | — | |
| SCHEMBL20188092 | 0.79 | MAPT (0.39) | HTR2CHTR2BHTR2A | |
| SCHEMBL18374263 | 0.79 | MAPT (0.39) | HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL20338506 | 0.77 | KDM4E (0.41) | HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL20338505 | 0.77 | KDM4E (0.41) | HTR2CHTR2BHTR2A | |
| SCHEMBL28408399 | 0.75 | HTT (0.44) | — | |
| SCHEMBL31447482 | 0.75 | HTT (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858344-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-12-08 | — | — | US | disclosed |
| WO-2018128720-A1 | URACIL CONTAINING COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-07-12 | — | — | WO | disclosed |
| US-9277619-B2 | Light emitting layer-forming solid material, organic electroluminescent device and method for producing the same | UDC Ireland (IE) | 2016-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858344-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | HTR2C 2804/4885HTR2B 2876/4885HTR2A 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.